**Appendix Table D10. Risk of bias in randomized controlled clinical trials that examined efficacy of botulinum toxin for migraine prevention in adults**

| **Reference** | **Masking** | **Intention to Treat Planned** | **Allocation Concealment** | **Adequacy of Randomization** | **Selective Outcome Reporting** | **Risk of Bias** | **Other Biases** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Aurora, 20101 | Double blind | Yes | Adequate | No | Unclear | Medium | Mean headache episodes during baseline & Mean migraine episodes during baseline are statistically different between group |
| Diener, 20102 | Double blind | Yes | Adequate | Yes | Unclear | Low |  |
| Saper, 20074 | Double blind | Yes | Unclear | Yes | Unclear | Low |  |
| Freitag, 20085 | Double blind | Yes | Unclear | Unclear (no tests conducted) | Unclear | Low | Poor reporting quality |
| Silberstein, 20006 | Double blind | Yes | Unclear | No | Unclear | Medium | Mean age differs by group: patients in vehicle group had higher mean age; Baseline frequencies of migraines of any severity were significantly lower in the 75-U BTX-A treatment group (4.40) than in the 25-U BTX-A (5.48) or vehicle (5.20) groups (P<.046). There was a statistically significant difference among groups in time since onset of migraines ( P=0.001), with a greater mean time since onset in the vehicle (27.4 years) and 25-U BTX-A (23.4 years) groups than in the 75-U BTX-A group (16.9 years). |
| Elkind, 20067 | Double blind | Yes | Unclear | Yes (See note) | Unclear | Low |  |
| Chankrachang\*, 20118\* | Double blind | Yes | Unclear | Yes | Unclear | Low | ITT planned only for efficacy measures |
| Petri\*, 20099\* | Double blind | Yes | Unclear | No | Yes | High | Mean age differs by groups |
| Mathew, 200510 | Double blind | Yes | Unclear | Yes | Unclear | Low |  |
| Silberstein, 200511 | Double blind | Yes | Unclear | Yes | Unclear | Low | does not provide loss at follow-up |
| Anand, 200612 | Double blind | No | Unclear | Unclear (Table not provided, but authors mentioned "Demographic characteristics of patients in both the groups were comparable". | Unclear | Medium | Concern regarding baseline severity: in text, authors report mean number of headache days at baseline (4 moderate to severe headache in trt group vs. 12.6 in placebo group) |
| Cady, 200813 | Double blind | No | Unclear | Yes | Unclear | Low |  |
| Vo, 200714 | Double blind | No | Unclear | Yes | Unclear | Low | Primary reason for attrition is attributable due the fluidality of personnel in a major military medical setting during a time of conflict |
| Aurora, 200715 | Double blind | Yes | Unclear | No | Unclear | Medium |  |
| Barrientos, 200316 | Double blind | Yes | Unclear | Yes | Unclear | Low |  |
| Relja, 200717 | Double blind | Yes | Unclear | Yes | Unclear | Low |  |

\* Trials of abobotulinumtoxin A